The Basel region has been named Europe’s premier destination for launching new drug device companies, according to a groundbreaking study released ahead of Pharmapack europe 2025.
This comprehensive research, which surveyed over 280 pharmaceutical executives globally, assessed critical factors such as operational expenses, talent availability, and infrastructure quality. Basel emerged as the clear frontrunner, securing one-third of the votes and outpacing other notable regions like Lombardy (18%), Catalunya (17%), the UK’s “Golden Triangle” (15%), and Baden-Württemberg in Germany (14%).
Pharmapack Europe, scheduled for January 22-23, 2025, at the Paris Expo, is renowned as Europe’s leading platform for pharmaceutical innovation. The event serves as a catalyst for cutting-edge advancements in drug delivery systems and lasting packaging,bridging the gap between start-ups and established industry leaders.
Sherma Ellis-Daal, brand director at Pharmapack Europe, highlighted the event’s importance in fostering innovation.“As one of the few places where early-stage innovators can connect with investors and scale-up partners, we play a vital role in advancing drug delivery innovation,” she said. “This research pinpoints the best locations for discovering and developing the next generation of technologies for novel devices or packaging—from concept to commercialization. One of the major hurdles to development success is access to the right partners for scaling, which is why we’re encouraging innovators from these major European hubs to attend the event.”
Switzerland and Germany also ranked highly for establishing new biomanufacturing facilities. Despite Basel’s higher labor costs, it was lauded for its unparalleled access to skilled professionals, top-tier research firms, and robust infrastructure, making it an ideal surroundings for innovation and growth.
This year’s Pharmapack Europe is expected to attract over 6,000 attendees and feature more than 370 exhibitors. A standout feature is the Start-Up Hub, which will spotlight over 20 emerging companies. The event has seen growing interest from german and Swiss executives keen on exploring opportunities in device and packaging innovations.
The full findings of the Pharmapack Report 2024 and Index will be unveiled during the event on CPHI-online.
Nevada’s Historic Step in Protecting Reproductive Rights: A Model for the Nation
In a landmark decision, Nevada has cemented its commitment to reproductive rights by passing a groundbreaking ballot initiative that enshrines these rights in its state constitution. This historic move, achieved in 2025, marks a notable victory for reproductive freedom advocates and sets a powerful example for other states across the country.
The initiative, which received overwhelming voter support, ensures that reproductive rights—including access to abortion and contraception—are protected at the highest legal level in Nevada. This constitutional safeguard is a direct response to the ongoing national debate surrounding reproductive healthcare and the increasing restrictions imposed in various states.
Dr.martinez, a leading expert on reproductive rights, emphasized the importance of Nevada’s decision, stating, “Nevada’s move is not just a win for its residents but also a model for other states. By embedding these rights in the constitution, nevada has created a durable framework that will withstand political shifts and judicial challenges.”
The initiative also reflects a broader movement toward prioritizing healthcare, affordable childcare, and family leave policies.advocates argue that these measures are essential for ensuring equity and supporting families across the state. Nevada’s progressive stance on these issues positions it as a leader in the fight for comprehensive reproductive and family care.
As the nation continues to grapple with the complexities of reproductive rights, Nevada’s bold step forward offers a blueprint for other states to follow. It underscores the power of grassroots activism and the importance of protecting essential rights through constitutional measures.
For more in-depth coverage of this historic progress and its implications,visit Archyde.
Stay informed with Archyde—your trusted source for breaking news and insightful analysis.
What opportunities and challenges does the convergence of technology and healthcare present for the drug device industry in Europe?
interview with Dr. Elena Müller,CEO of InnovatePharma Basel,on Basel’s Emergence as Europe’s Premier Hub for Drug Device Companies
By Archyde news
Archyde news: Dr.Müller, thank you for joining us today.Basel has recently been named Europe’s top destination for launching new drug device companies. As the CEO of InnovatePharma Basel, a leading innovator in drug delivery systems, what are your thoughts on this recognition?
Dr. Elena Müller: Thank you for having me. It’s an exciting time for Basel and the entire pharmaceutical innovation ecosystem.this recognition is a testament to the region’s unique combination of talent, infrastructure, and collaborative spirit. Basel has long been a hub for pharmaceutical and biotech innovation, but this study underscores its growing prominence in the drug device sector. It’s a validation of the hard work and investment that has gone into creating an environment where innovation thrives.
Archyde News: The study highlighted Basel’s access to skilled professionals, top-tier research firms, and robust infrastructure as key factors. How does this ecosystem benefit companies like InnovatePharma Basel?
Dr.Müller: the ecosystem here is unparalleled.basel is home to some of the world’s leading pharmaceutical companies, research institutions, and startups. This concentration of expertise creates a fertile ground for collaboration and knowledge-sharing. For InnovatePharma basel, it means we have access to cutting-edge research, a highly skilled workforce, and state-of-the-art facilities. Additionally, the proximity to academic institutions like the University of Basel and ETH Zurich ensures a steady pipeline of talent and innovation.
Archyde News: The study also noted that basel’s higher labor costs were offset by these advantages.How do you balance the cost challenges with the benefits of operating in basel?
Dr. Müller: It’s true that labor costs in Basel are higher compared to some other regions, but the value we derive from being here far outweighs the expenses. The quality of talent, the efficiency of our operations, and the ability to collaborate with industry leaders and researchers enable us to innovate faster and bring products to market more effectively. In the long run, this creates a competitive advantage that justifies the investment.
Archyde News: Pharmapack Europe 2025 is coming up, and Sherma Ellis-daal, the brand director, emphasized the event’s role in connecting innovators with investors and scale-up partners. How critically important are events like Pharmapack for companies like yours?
Dr. Müller: Events like Pharmapack Europe are absolutely critical. They provide a platform for us to showcase our innovations, connect with potential partners, and stay abreast of the latest trends in drug delivery and packaging. For a company like ours, which is focused on developing novel drug delivery systems, these connections are invaluable.They help us bridge the gap between concept and commercialization, which is one of the biggest challenges in our industry.
Archyde News: What specific innovations is InnovatePharma Basel working on, and how do you see them impacting the pharmaceutical industry?
Dr. Müller: We’re currently developing a next-generation drug delivery platform that combines smart technology with biocompatible materials to improve patient adherence and outcomes.Our goal is to make drug delivery more precise, efficient, and user-pleasant. This has the potential to revolutionize how patients manage chronic conditions and how healthcare providers administer treatments. We believe our innovations will not only enhance patient care but also reduce healthcare costs in the long term.
Archyde News: Looking ahead, what do you see as the biggest opportunities and challenges for the drug device industry in Europe?
Dr. Müller: The biggest chance lies in the convergence of technology and healthcare. Advances in AI, IoT, and materials science are opening up new possibilities for drug delivery and patient monitoring. Tho, the challenge is navigating the regulatory landscape and ensuring that these innovations are safe, effective, and accessible. Collaboration between industry, regulators, and academia will be key to overcoming these challenges and unlocking the full potential of the drug device industry.
Archyde News: what advice would you give to startups looking to establish themselves in the drug device sector, particularly in a competitive hub like Basel?
Dr. Müller: My advice would be to focus on building strong partnerships and leveraging the ecosystem. Basel offers a wealth of resources, but success depends on how effectively you can tap into them. Be proactive in seeking collaborations, stay agile, and prioritize innovation. And most importantly, attend events like Pharmapack Europe to connect with the right people and stay ahead of the curve.
Archyde News: Thank you, Dr.Müller, for sharing your insights. We look forward to seeing InnovatePharma Basel’s continued success and contributions to the pharmaceutical industry.
Dr. Müller: Thank you. It’s an exciting journey,and we’re just getting started.
